Skin Disorders News

BOSTON — Chronic spontaneous urticaria has a negative impact on patients’ lives, including on both mental and physical health and daily activities, according to a poster presented at the American Academy of Dermatology Annual Meeting.

Autoimmune treatments accounted for more than half of all specialty drug growth in 2021, according to a drug trend report released by CVS Health.

PHOENIX — Young children with atopic dermatitis demonstrated a significant disease burden impacting their quality of life, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

PHOENIX — Patients with H1 antihistamine-resistant chronic spontaneous urticaria experienced improvements with dupilumab, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

PHOENIX — Urticaria and/or angioedema events comprised 13% of the adverse reports from clinicians after mRNA vaccinations for COVID-19, according to a presentation at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Delayed hypersensitivity to vaccines is not uncommon but also does not typically contraindicate further vaccination, and patch testing can be used to determine the cause, according to a study published in Allergy & Asthma Proceedings.

Children with atopic dermatitis generally experienced the most intense itching in the early evening or bedtime, approximately 3 hours before they fell asleep, according to a study published in Annals of Allergy, Asthma & Immunology.

The development of asthma is more likely in patients with persistent or severe atopic dermatitis, according to a study.

Treatment with tralokinumab significantly improved symptoms among adolescents with moderate to severe atopic dermatitis, according to a study presented at the Western Society of Allergy, Asthma & Immunology Annual Scientific Meeting.

The FDA has accepted for priority review a supplemental biologics application for Dupixent that could allow treatment of moderate to severe atopic dermatitis in patients aged 6 months to 5 years, Regeneron announced in a press release.